Literature DB >> 25355276

3D-QSAR modeling and molecular docking study on Mer kinase inhibitors of pyridine-substituted pyrimidines.

Zhuang Yu1, Xianchao Li, Cuizhu Ge, Hongzong Si, Lianhua Cui, Hua Gao, Yunbo Duan, Honglin Zhai.   

Abstract

Mer kinase is a novel therapeutic target for many cancers, and overexpression of Mer receptor tyrosine kinase has been observed in several kinds of tumors. To deeply understand the structure-activity correlation of a series of pyridine/pyrimidine analogs as potent Mer inhibitors, a combined molecular docking and three-dimensional quantitative structure-activity relationship modeling was carried out. A comparative molecular similarity indices analysis model was developed based on the maximum common substructure alignment. The optimum model exhibited statistically significant results: the cross-validated correlation coefficient q2 was 0.599, and non-cross-validated r2 value was 0.984. Furthermore, the results of internal validation such as bootstrapping, Y-randomization as well as external validation (the external predictive correlation coefficient r2 ext = 0.728) confirmed the rationality and good predictive ability of the model. Using the crystal structure of Mer kinase, the selected pyridine/pyrimidine compounds were docked into the enzyme active site. Some key amino acid residues were determined, and hydrogen bonding and hydrophobic interactions between Mer kinase and inhibitors were identified. The satisfactory results from this study may aid in the research and development of novel potent Mer kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355276     DOI: 10.1007/s11030-014-9556-0

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  41 in total

1.  3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.

Authors:  Juan Du; Jin Qin; Huanxiang Liu; Xiaojun Yao
Journal:  J Mol Graph Model       Date:  2008-03-16       Impact factor: 2.518

2.  Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase.

Authors:  L Ling; D Templeton; H J Kung
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

3.  Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK).

Authors:  C Rochlitz; A Lohri; M Bacchi; M Schmidt; S Nagel; M Fopp; M F Fey; R Herrmann; A Neubauer
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

Review 4.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

5.  Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1.

Authors:  K-Y Tai; Y-S Shieh; C-S Lee; S-G Shiah; C-W Wu
Journal:  Oncogene       Date:  2008-03-17       Impact factor: 9.867

6.  The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity.

Authors:  Edward M Behrens; Paul Gadue; Shun-you Gong; Stacey Garrett; Paul L Stein; Philip L Cohen
Journal:  Eur J Immunol       Date:  2003-08       Impact factor: 5.532

7.  UNC1062, a new and potent Mer inhibitor.

Authors:  Jing Liu; Weihe Zhang; Michael A Stashko; Deborah Deryckere; Christopher T Cummings; Debra Hunter; Chao Yang; Chatura N Jayakody; Nancy Cheng; Catherine Simpson; Jacqueline Norris-Drouin; Susan Sather; Dmitri Kireev; William P Janzen; H Shelton Earp; Douglas K Graham; Stephen V Frye; Xiaodong Wang
Journal:  Eur J Med Chem       Date:  2013-04-02       Impact factor: 6.514

8.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

9.  Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Authors:  R M A Linger; R A Cohen; C T Cummings; S Sather; J Migdall-Wilson; D H G Middleton; X Lu; A E Barón; W A Franklin; D T Merrick; P Jedlicka; D DeRyckere; L E Heasley; D K Graham
Journal:  Oncogene       Date:  2012-08-13       Impact factor: 9.867

Review 10.  Computational methods for drug design and discovery: focus on China.

Authors:  Mingyue Zheng; Xian Liu; Yuan Xu; Honglin Li; Cheng Luo; Hualiang Jiang
Journal:  Trends Pharmacol Sci       Date:  2013-09-11       Impact factor: 14.819

View more
  2 in total

1.  QSAR modeling and in silico design of small-molecule inhibitors targeting the interaction between E3 ligase VHL and HIF-1α.

Authors:  Jing Pan; Yanmin Zhang; Ting Ran; Anyang Xu; Xin Qiao; Lingfeng Yin; Weineng Zhou; Lu Zhu; Junnan Zhao; Tao Lu; Yadong Chen; Yulei Jiang
Journal:  Mol Divers       Date:  2017-07-08       Impact factor: 2.943

Review 2.  An overview of kinase downregulators and recent advances in discovery approaches.

Authors:  Beilei Wang; Hong Wu; Chen Hu; Haizhen Wang; Jing Liu; Wenchao Wang; Qingsong Liu
Journal:  Signal Transduct Target Ther       Date:  2021-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.